drugset
drugset / Trial / NCT06569758

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

NCT06569758 ↗

Phase 1 Recruiting 76 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)

Timeline

Start
2024-09-24
Primary completion
2027-09-02
Completion
2027-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject GenSci098 Unknown 15 mg Subcutaneous
Subject GenSci098 Unknown 45 mg Subcutaneous
Subject GenSci098 Unknown 90 mg Subcutaneous
Subject GenSci098 Unknown 180 mg Subcutaneous
Subject GenSci098 Unknown 270 mg Subcutaneous

Indications

endocrine exophthalmos